ANIX CIK: 715446

Anixa Biosciences Inc

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
36.0
FY22:
30.2
FY23:
25.4
FY24:
21.4
FY25:
15.9
(positive)
Change from FY21 to FY25
millions USD
FY21:
0.25
FY22:
0.21
FY23:
0.17
FY24:
0.23
FY25:
0.19
Total assets
Change from FY21 to FY25
millions USD
FY21:
36.3
FY22:
30.4
FY23:
25.5
FY24:
21.6
FY25:
16.1

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
1.27
FY22:
2.04
FY23:
2.03
FY24:
2.50
FY25:
1.97
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.22
FY22:
0.18
FY23:
0.12
FY24:
0.20
FY25:
0.16
(positive)
Change from FY21 to FY25
millions USD
FY21:
35.4
FY22:
29.0
FY23:
24.3
FY24:
20.0
FY25:
15.2
Total liabilities & equity
Change from FY21 to FY23
millions USD
FY21:
36.9
FY22:
31.3
FY23:
26.5
FY24:
–
FY25:
–

All amounts in millions USD Data source:SEC EDGAR